NCT06325059 The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases
| NCT ID | NCT06325059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Meyer Children's Hospital IRCCS |
| Condition | Nephropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-03-22 |
| Primary Completion | 2047-03-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-03-22 with a primary completion date of 2047-03-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Renal progenitors are a subset of parietal epithelial cells (PECs) localized at the urinary pole of Bowman's capsule. Experimental models of podocyte damage showed that PECs can potentially regenerate lost podocytes by migrating from Bowman's capsule to the glomerular tuft, acquiring the morphological and functional features of mature podocytes. Podocyte loss and damage, as well as the inability of PECs to replace lost podocytes, lead to glomerular scarring and chronic kidney disease (CKD) progression. In addition, the investigators of the present study and others have recently demonstrated the existence of a specific subpopulation of tubular cells in the human kidney with a high potential for regeneration and resistance to death, thus acting as tubular progenitors. These cells are involved in tubular response to damage during acute kidney injury (AKI) trough endoreplication (polyploidization). Kidney biopsy is the cornerstone of diagnosis in many kidney diseases leading to CKD and AKI, allowing unambiguous diagnosis in some cases and presumptive diagnosis of ongoing disease in others. Very recently, super resolution imaging techniques proved to maintain current diagnostic standards while allowing to study morphological features of pathophysiological mechanisms of glomerular and tubular diseases. The rationale of this project is to study the role of renal progenitors (PECs and tubular progenitors) in the pathogenesis of CKD and AKI trough super resolution imaging applied to human renal biopsies, to the aim of identifying relevant connections with clinical data and markers of damage and/or disease progression.
Eligibility Criteria
Inclusion Criteria: * Patients with glomerular diseases undergoing renal biopsy (e.g., rapidly progressive glomerulonephritis, minimal change disease, focal segmental glomerulosclerosis, diabetic nephropathy, lupus nephritis, membranous nephropathy, IgA nephropathy, etc) * Patients with AKI, regardless of the nature of the damage (septal, ischemic, toxic, or unknown). * Signed informed consent form Exclusion Criteria: * Sample insufficient and/or unavailable
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06325059 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 17 Years, studying Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06325059 currently recruiting?
Yes, NCT06325059 is actively recruiting participants. Contact the research team at paola.romagnani@meyer.it for enrollment information.
Where is the NCT06325059 trial being conducted?
This trial is being conducted at Florence, Italy.
Who is sponsoring the NCT06325059 clinical trial?
NCT06325059 is sponsored by Meyer Children's Hospital IRCCS. The trial plans to enroll 200 participants.